Zhixin Finance and Economics APP News, Henan Lingrui Pharmaceutical (600285.SH) released the report for the first three quarters of 2024. During the reporting period, the company achieved revenue of 2.759 billion yuan, a year-on-year increase of 10.07%; net income attributable to shareholders of the listed company was 0.574 billion yuan, a year-on-year increase of 23.10%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.541 billion yuan, a year-on-year increase of 22.54%; basic earnings per share was 1.024 yuan per share.